O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|S2|17-17

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.S2, 2015-06, pp. : 17-17

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 79-86

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials

By  

HEPATOLOGY, Vol. 62, Iss. 1, 2015-07 ,pp. : 25-30

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost‐effectiveness of all‐oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 6, 2015-03 ,pp. : 544-563

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States

By  

HEPATOLOGY, Vol. 61, Iss. 5, 2015-05 ,pp. : 1471-1478

John Wiley & Sons Inc

Access to resources Recommend Favorite

P152: Real‐world effectiveness of Ledipasvir/Sofosbuvir 8 weeks chronic hepatitis C treatment

By  

JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol. 22, Iss. S2, 2015-06 ,pp. : 95-96

John Wiley & Sons Inc

Access to resources Recommend Favorite